Comparative Pharmacology
Head-to-head clinical analysis: HALFAN versus PRIMAQUINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALFAN versus PRIMAQUINE PHOSPHATE.
HALFAN vs PRIMAQUINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
Adults: 500 mg orally once daily.
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
None Documented
None Documented
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Category C
Category D/X
Antimalarial
Antimalarial